Breaking News

Netherlands Jumps to 2-0 Lead Over Brazil in World Cup Game
Tweet TWEET

Christie Assure Program Expands Globally Revolutionizing VeinViewer Training for Healthcare Facilities

  Christie Assure Program Expands Globally Revolutionizing VeinViewer Training
  for Healthcare Facilities

Business Wire

MEMPHIS, Tenn. -- August 26, 2013

Christie Medical Holdings, Inc., today announced the expansion of its
industry-leading Christie Assure Program to hospitals and physician offices in
over 40 countries using the HD VeinViewer® vein illumination products which
project vascular imaging on the skin surface.

The five-year program includes warranty, access to online clinical education
and an upgrade program to the latest Christie product platforms. An
industry-first, the Christie Assure Program represents a significant
leadership investment in seeing the end customer achieve utilization and
results through Christie technologies.

Chris Schnee, GM and VP at Christie Medical Holdings, said, “We launched
VeinViewer^GS internationally in 2008. Today 3^rd, 4^th and 5^th generation
VeinViewers are being sold around the world. Through our technology leadership
and support, we aim to help VeinViewer users achieve an increase in patient
satisfaction, a potential reduction in patient risk and infection, and
maximize healthcare economic benefits.”

The Christie Assure Program was built upon the results of a thorough survey
where customers asked for help to achieve the same results which have proven
the benefits of VeinViewer technology in clinical studies. Results show up to
a 100 percent increase in first-stick success and patient satisfaction ratings
and a 50 percent decrease in medically unnecessary PICC lines. The goal is to
maximize the positive return each facility receives from its investment and to
improve patient care.

Christie Assure Program terms apply.

Recently, the company’s three clinical studies encompassing 3,000 data points
compared VeinViewer’s measurements to that of ultrasound, the industry gold
standard. The studies, vetted and approved by Institutional Review Board (IRB)
Services, demonstrated that VeinViewer measured accurate within half a
millimeter on average, and for veins most commonly accessed for a peripheral
IV (3mm-7mm wide), it projected near perfect vein widths (+/- 0.06mm).

VeinViewer has undergone ten stringent peer reviews since 2006. Third-party
medical peer reviews demonstrate the statistically significant clinical
effectiveness of VeinViewer, and often evaluate potential savings to the
bottom line.

VeinViewer technology was developed with the aid of the engineering
capabilities and resources of parent company Christie Digital Systems, a
leading global visual technology firm with more than 80 years of experience in
the projection systems industry. VeinViewer is the first and only device on
the market to use: harmless near-infrared light, DLP® technologies, exclusive
technology such as Active Vascular Imaging Navigation (AVIN™) providing the
demanded Pre, During and Post-access (PDP) benefits, TrueView imaging accuracy
in projected vein-widths which is three to ten times more accurate than
competition, and technologies such as Df^2 (Digital full field) to illuminate
the only real-time HD digital image of subcutaneous vasculature and blood
patterns directly onto the skin surface.Although designed for assistance in
IV starts and blood draws, VeinViewer has proven beneficial in spider and
varicose vein treatment.

To learn more about Christie  product offerings please visit
www.veinviewer.com.

About Christie Medical Holdings, Inc.

Christie Medical Holdings Inc. is a global company based in Memphis, Tenn.,
that discovers, develops and commercializes medical technologies. The
company’s market-leading product, VeinViewer®, is a mobile vascular imaging
system that allows health care providers to clearly see accessible vasculature
as a real time HD image, directly on the surface of the skin. Christie Medical
Holdings Inc. is owned by Christie Digital Systems Inc., a global visual
technologies company and a subsidiary of Ushio Inc., Japan (JP:6925). For more
information on Christie Digital Systems or Christie Medical Holdings, visit
www.christiedigital.com.

Follow us on Twitter @veinviewer

DLP® is a registered trademark of Texas Instruments.

Contact:

Christie Medical Holdings, Inc.
Carmen Robert, 519-572-5824
carmen.robert@christiedigital.com